Dip**** it is privatized.
Those are drug pushers.The really evil kind because they get government agencies to tell you their poison is good for you.
Hedge funder buys rights to AIDS treatment pill and raises price from $13.50 to $750
- Thread starter Locutus
- Start date
Dip**** it is privatized.
Those are drug pushers.The really evil kind because they get government agencies to tell you their poison is good for you.
They can have a blind trust or have their wife hold the portfolio but they cannot discuss it with either the trust manager or their wife...which I'm sure they never would. :roll:
Bullet would be too good for him...an infection with AIDS would be more suitable.
Free market is when consumers and vendors agree on things.
This goes waaay beyond capitalism even; straight to out and out usury and gouging.
The US Senate has launched a bipartisan investigation into prescription drug pricing, targeting Valeant, Turing Pharma, Retrophin, and Rodelis in particular.
In a statement, Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Missouri) raised concerns that drug price increases were often occurring for older, off-patent drugs after acquisitions or mergers of pharmaceutical companies.
In a letter to Valeant the senators asked for documents surrounding the company’s recent acquisitions of the rights to sell Isuprel, Nitropress, and Cuprimine.
They noted that the price of Nitropress which is used to treat cardiac arrests, jumped from $215.46 per vial to $1346 per vial.
Likewise, Isuprel’s price jumped 820% from $4489 for 25 0.2-mL ampules to $36,811.
The value of Cuprimine increased by 2949% from $888 for 100 250-mg capsules to $26,189.
Retrophin’s letter was focused on its license of the rights to sell Thiola from Mission Pharmacal Company and the increase of the kidney disease drug from $1.50 to $30 per tablet.
Rodelis increased the price from $500 to $10,800, but eventually returned the rights to sell the drug to the Chao Center, which had originally sold the tuberculosis drug.
The Senate Special Committee on Aging, led by Collins and McClaskill, has scheduled an initial hearing for December 9, 2015.
http://www.pharmacytimes.com/news/prescription-drug-pricing-under-senate-investigation
In a statement, Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Missouri) raised concerns that drug price increases were often occurring for older, off-patent drugs after acquisitions or mergers of pharmaceutical companies.
In a letter to Valeant the senators asked for documents surrounding the company’s recent acquisitions of the rights to sell Isuprel, Nitropress, and Cuprimine.
They noted that the price of Nitropress which is used to treat cardiac arrests, jumped from $215.46 per vial to $1346 per vial.
Likewise, Isuprel’s price jumped 820% from $4489 for 25 0.2-mL ampules to $36,811.
The value of Cuprimine increased by 2949% from $888 for 100 250-mg capsules to $26,189.
Retrophin’s letter was focused on its license of the rights to sell Thiola from Mission Pharmacal Company and the increase of the kidney disease drug from $1.50 to $30 per tablet.
Rodelis increased the price from $500 to $10,800, but eventually returned the rights to sell the drug to the Chao Center, which had originally sold the tuberculosis drug.
The Senate Special Committee on Aging, led by Collins and McClaskill, has scheduled an initial hearing for December 9, 2015.
http://www.pharmacytimes.com/news/prescription-drug-pricing-under-senate-investigation
I hate to necro troll, but sometimes people say such stupid things, it begs for it...
Ummm, pharma is a private industry, lol.
After weeks of criticism from patients, doctors and other drugmakers for hiking a life-saving medicine's price more than fifty-fold, Turing Pharmaceuticals is reneging on its pledge to cut the $750-per-pill price.
Instead, the small biotech company is reducing what it charges hospitals, by up to 50 per cent, for its parasitic infection treatment, Daraprim. Most patients' copayments will be capped at $10 or less a month. But insurers will be stuck with the bulk of the $750 tab. That drives up future treatment and insurance costs.
Daraprim is a 62-year-old pill whose patent expired decades ago. It's the preferred treatment for a rare parasitic infection, toxoplasmosis, which mainly threatens people with weak immune systems, such as HIV and organ transplant patients, and pregnant women, because it can kill their baby.
Turing's move comes after a pharmacy that compounds prescription drugs for individual patients, Imprimis Pharmaceuticals, started selling a custom-made version for 99 cents per capsule.
"This medication can be made for pennies. They need to reduce the price to what it was before," he said.
Dr. Warren Dinges of the Seattle Infectious Diseases Clinic said he's treating an HIV patient who got toxoplasmosis in his eye, damaging his vision. The man, an artist, tried to fill a prescription Dinges wrote for Daraprim but was told by his pharmacy that it wasn't in stock and would cost about $27,000 for a month's supply.
Dinges instead got Imprimis to make up a custom version for barely $100 per month.
more
Turing reneges on cutting US$750-a-pill drug's price, rival's new 99-cent version selling well | CTV News
Instead, the small biotech company is reducing what it charges hospitals, by up to 50 per cent, for its parasitic infection treatment, Daraprim. Most patients' copayments will be capped at $10 or less a month. But insurers will be stuck with the bulk of the $750 tab. That drives up future treatment and insurance costs.
Daraprim is a 62-year-old pill whose patent expired decades ago. It's the preferred treatment for a rare parasitic infection, toxoplasmosis, which mainly threatens people with weak immune systems, such as HIV and organ transplant patients, and pregnant women, because it can kill their baby.
Turing's move comes after a pharmacy that compounds prescription drugs for individual patients, Imprimis Pharmaceuticals, started selling a custom-made version for 99 cents per capsule.
"This medication can be made for pennies. They need to reduce the price to what it was before," he said.
Dr. Warren Dinges of the Seattle Infectious Diseases Clinic said he's treating an HIV patient who got toxoplasmosis in his eye, damaging his vision. The man, an artist, tried to fill a prescription Dinges wrote for Daraprim but was told by his pharmacy that it wasn't in stock and would cost about $27,000 for a month's supply.
Dinges instead got Imprimis to make up a custom version for barely $100 per month.
more
Turing reneges on cutting US$750-a-pill drug's price, rival's new 99-cent version selling well | CTV News
Express Scripts, which manages prescription for tens of millions of Americans, will promote the use of the $1 per pill alternative to Turing’s $750 per pill drug, potentially sparing tens of thousands of dollars in treatment costs per patient. That cheap alternative is already being made and sold by Imprimis Pharmaceuticals in San Diego.
In a press release, Steve Miller, senior vice president and chief medical officer of Express Scripts, said that "leveraging our expertise to improve access and affordability to an important medication is the right thing to do..."
The move comes amid an intense uproar of anger towards Turing, which raised the cost of Daraprim by more than 5,000 percent in September. The company became the poster-child for pharmaceutical price gouging.
In October, Imprimis responded by announcing that it would make a cheap alternative, a compounded drug. That compounded drug includes Daraprim’s active ingredient, pyrimethamine, as well as leucovorin, which helps prevent side-effects. Both Daraprim and the compounded alternative treat toxoplasmosis, a parasitic infection that often strikes people with compromised immune systems, such as people with AIDS.
more...
$1 pill alternative to Turing’s $750 pill gets boost from drug manager | Ars Technica
In a press release, Steve Miller, senior vice president and chief medical officer of Express Scripts, said that "leveraging our expertise to improve access and affordability to an important medication is the right thing to do..."
The move comes amid an intense uproar of anger towards Turing, which raised the cost of Daraprim by more than 5,000 percent in September. The company became the poster-child for pharmaceutical price gouging.
In October, Imprimis responded by announcing that it would make a cheap alternative, a compounded drug. That compounded drug includes Daraprim’s active ingredient, pyrimethamine, as well as leucovorin, which helps prevent side-effects. Both Daraprim and the compounded alternative treat toxoplasmosis, a parasitic infection that often strikes people with compromised immune systems, such as people with AIDS.
more...
$1 pill alternative to Turing’s $750 pill gets boost from drug manager | Ars Technica
Martin Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges
Martin Shkreli Arrested on Securities Fraud Charges
Martin Shkreli Arrested on Securities Fraud Charges
Can you show me where anyone is arguing for that?
If I could give you ten thousand thumbs up for this post; I would.
